This work elucidated the pharmacological effects and molecular mechanisms of endostar combined with cisplatin against NSCLC and further supported that METTL3 and FMOD could serve as therapeutic targets for NSCLC. This evidence concerns the gene FMOD and non-small cell lung carcinoma.